Chromosomal Structural Variation Detection: Testing Methods, Samples, and Applications

Chromosomal structural variation detection identifies deletions, duplications, inversions, translocations, and copy number variations (CNVs) across the genome using cytogenetic and molecular technologies such as G-banded karyotyping, FISH, chromosomal microarray analysis, and next-generation sequencing. Accredited third-party laboratories performing these tests operate under ISO 15189 and ISO/IEC 17025 quality management systems and follow internationally recognized clinical genetics technical standards. This guide explains the principle, sample requirements, testing items, detection methods, and practical applications of chromosomal structural variation analysis for clinical, reproductive, oncology, and research purposes.

Technical Overview

Chromosomal structural variation detection refers to the laboratory determination of genome-scale rearrangements that alter the structure, orientation, or copy number of chromosomes. Structural variations (SVs) conventionally encompass variants larger than approximately 1 kilobase and include deletions, duplications, insertions, inversions, reciprocal and Robertsonian translocations, ring chromosomes, isochromosomes, and complex rearrangements. Among these, copy number variants (CNVs) such as microdeletions and microduplications represent the most frequently observed clinically significant class.

Structural variations are established causes of developmental delay, intellectual disability, congenital anomalies, autism spectrum disorders, infertility, recurrent pregnancy loss, and both hematologic malignancies and solid tumors. Precise detection and breakpoint characterization are therefore essential for diagnosis, prognosis, therapy selection, and genetic counseling.

• Deletions and microdeletions (loss of genomic segments)
• Duplications, amplifications, and copy number gains
• Inversions and insertions (balanced or unbalanced rearrangements)
• Reciprocal and Robertsonian translocations
• Ring chromosomes, isochromosomes, and marker chromosomes
• Copy-neutral changes such as uniparental disomy and regions of homozygosity

Because no single platform resolves every class of structural variant, testing is performed with complementary technologies spanning a wide resolution range: conventional karyotyping at approximately 5 to 10 Mb, fluorescence in situ hybridization at roughly 100 to 200 kb, chromosomal microarrays at 30 to 100 kb, and whole-genome sequencing approaching single base-pair breakpoint resolution. Analyses are carried out by accredited third-party laboratories and clinical genetics laboratories within quality frameworks conforming to ISO 15189 and ISO/IEC 17025, with variant interpretation following internationally recognized cytogenomic professional standards.

Testing Samples

Peripheral Blood

Sodium heparin tubes of 2 to 5 mL are required for cultured lymphocyte karyotyping, while EDTA tubes of 2 to 3 mL are suitable for DNA-based assays including chromosomal microarray, MLPA, and sequencing-based CNV analysis. Samples should be transported at ambient temperature and processed within 24 to 72 hours of collection.

Prenatal Specimens

Amniotic fluid (typically 15 to 20 mL from gestational week 16 or later), chorionic villus samples (10 to 20 mg from weeks 10 to 13), and fetal cord blood are accepted for prenatal structural variation testing. Maternal cell contamination testing is routinely performed to confirm the fetal origin of the specimen.

Bone Marrow and Hematologic Samples

Bone marrow aspirate of 1 to 2 mL in sodium heparin is used for karyotyping of suspected leukemias and lymphomas, while EDTA bone marrow or peripheral blood is suitable for FISH, fusion transcript analysis, and sequencing-based assays.

Tumor Tissue

Fresh or frozen tissue supports karyotyping and FISH, whereas formalin-fixed paraffin-embedded (FFPE) sections are applicable for interphase FISH and, when DNA quality permits, array or sequencing-based copy number profiling.

Products of Conception and Fetal Tissue

Cleaned fetal or placental tissue can be analyzed by chromosomal microarray or low-pass whole-genome sequencing to determine whether a structural or numerical chromosomal abnormality caused the pregnancy loss, which directly informs recurrence risk counseling.

Extracted DNA, Buccal Swabs, and Cell Lines

Genomic DNA should generally meet purity criteria of approximately 1.8 to 2.0 at the A260/A280 ratio, with concentration of at least 50 ng per microliter and total yield of at least 1 microgram depending on the assay. Established cell lines may also be submitted for karyotype stability assessment.

Testing Items

Testing items cover the full spectrum of structural variation classes, tailored to the clinical question and specimen type:

• Genome-wide CNV detection, including microdeletions and microduplications
• Screening for known recurrent syndromic loci, such as DiGeorge, Williams, Prader-Willi or Angelman, Smith-Magenis, and Miller-Dieker regions
• Subtelomeric rearrangement analysis
• Balanced rearrangements, including reciprocal translocations, Robertsonian translocations, inversions, and insertions
• Characterization of derivative and marker chromosomes of unknown origin
• Mosaicism detection and quantitative estimation of abnormal cell lineages
• Regions of homozygosity, copy-neutral loss of heterozygosity, and uniparental disomy by SNP array
• Oncology fusions and rearrangements, including BCR-ABL1, PML-RARA, IGH-BCL2, ALK, RET, and NTRK gene rearrangements
• Base-pair level breakpoint mapping for exact junction characterization and custom probe design
• In vitro chromosomal aberration testing for genotoxicity assessment of chemicals and medical devices under frameworks such as ISO 10993-3

Testing Methods

G-Banded Karyotyping

Metaphase chromosome spreads prepared from cultured cells are stained to produce 400 to 550 band-level resolution, enabling genome-wide visualization of both balanced and unbalanced abnormalities larger than roughly 5 to 10 Mb. Results are reported using International System for Human Cytogenomic Nomenclature (ISCN) conventions.

Fluorescence In Situ Hybridization (FISH)

Locus-specific, centromeric, subtelomeric, and whole-chromosome painting probes provide targeted detection or confirmation of known rearrangements. Interphase FISH is applicable to non-dividing cells, FFPE tissue, and mosaic monitoring, with rapid turnaround typically within 24 to 72 hours.

Chromosomal Microarray Analysis (Array CGH and SNP Array)

Microarray platforms deliver genome-wide CNV detection at 30 to 100 kb resolution from uncultured DNA, making array testing a first-tier diagnostic test for developmental delay, intellectual disability, autism spectrum disorders, and multiple congenital anomalies according to international consensus guidelines. SNP arrays additionally reveal regions of homozygosity and uniparental disomy. Arrays do not detect truly balanced rearrangements.

Multiplex Ligation-dependent Probe Amplification (MLPA)

MLPA provides cost-effective, targeted CNV screening of defined loci such as subtelomeric regions and known syndrome panels using minimal DNA input, and is well suited to carrier testing in relatives of affected individuals.

Quantitative PCR and Digital PCR

qPCR and droplet digital PCR offer rapid orthogonal confirmation of candidate CNVs, breakpoint junctions, and dosage changes, with high sensitivity for low-level mosaicism when digital partitioning is applied.

Next-Generation Sequencing

Low-pass whole-genome sequencing (CNV-seq) provides genome-wide copy number profiling with low DNA input down to sub-megabase resolution. Full whole-genome sequencing additionally detects balanced translocations, inversions, and complex rearrangements with nucleotide-level breakpoint resolution. RNA sequencing can be applied to fusion transcript discovery in oncology specimens.

Optical Genome Mapping

Ultra-long labeled DNA molecules are analyzed to detect balanced and unbalanced structural variants from approximately 500 bp upward, offering an emerging complement to karyotyping with substantially improved resolution and phased structural context.

Applications

Chromosomal structural variation detection supports diverse clinical and research scenarios:

• Clinical genetics: postnatal etiologic diagnosis of developmental delay, intellectual disability, multiple congenital anomalies, and autism spectrum disorders
• Prenatal diagnosis: evaluation of abnormal ultrasound findings, high-risk screening results, or known parental rearrangements
• Preimplantation genetic testing for structural rearrangements (PGT-SR) within assisted reproduction programs
• Reproductive genetics: workups of infertility, recurrent miscarriage, non-obstructive azoospermia, and premature ovarian insufficiency
• Oncology: diagnosis, risk stratification, therapy selection, and residual disease monitoring of leukemias and lymphomas, plus fusion testing in solid tumors
• Products of conception evaluation to clarify the cause of pregnancy loss and guide recurrence counseling
• Genetic toxicology: chromosomal aberration and micronucleus testing of chemicals, pharmaceuticals, and medical devices under ISO 10993-3 and Good Laboratory Practice frameworks
• Agricultural and comparative genomics: breeding selection, karyotype diversity assessment, and genome evolution studies in plants and animals

FAQ

Q: What resolution can each method achieve?

A: G-banded karyotyping generally resolves abnormalities of 5 to 10 Mb and above, FISH detects targets of roughly 100 to 200 kb depending on probe design, chromosomal microarrays reach 30 to 100 kb resolution, optical genome mapping resolves variants from about 500 bp, and whole-genome sequencing can define breakpoints at single base-pair precision.

Q: Can chromosomal microarray detect balanced translocations?

A: No. Arrays measure DNA dosage and therefore detect only unbalanced copy number changes. Balanced translocations, inversions, and insertions without dosage change require karyotyping, FISH, whole-genome sequencing, or optical genome mapping.

Q: What is the typical turnaround time?

A: FISH results are often available within 2 to 5 working days, karyotyping requires 7 to 14 days due to cell culture, chromosomal microarray typically takes 7 to 10 working days, and sequencing-based analyses generally require 2 to 4 weeks including bioinformatics and interpretation.

Q: How is mosaicism assessed?

A: Karyotyping evaluates 20 metaphases as standard and additional cells when mosaicism is suspected, FISH can score hundreds of interphase nuclei, and array or digital PCR approaches can approximate mosaic ratios quantitatively, with sensitivity depending on the platform and level of abnormal cells.

Q: How are results interpreted and reported?

A: Findings are described using ISCN nomenclature and genome coordinates referenced to GRCh37 or GRCh38, with copy number variants classified according to internationally recognized medical genetics interpretation standards. Reports include method capabilities and limitations, detection thresholds, and clinically relevant correlations to support genetic counseling.

Q: How is test quality assured?

A: Accredited third-party laboratories maintain quality systems conforming to ISO 15189 or ISO/IEC 17025, apply validated workflows with positive and negative controls, participate in external proficiency testing schemes, and document full analytical traceability from specimen receipt to reporting.